Megan Hollasch

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication OncologyLive, aiding in all aspects of the publication process, as well as content for OncLive.com.

Articles

Durvalumab Plus Chemo May be Promising Neoadjuvant Option in UTUC

February 25th 2025

A phase 3 study will be initiated after completion of the first neoadjuvant phase 2 trial of platinum-based chemotherapy plus immunotherapy in UTUC.

Efineptakin Alfa Represents Potentially Effective Option in Kaposi Sarcoma

February 24th 2025

The long-acting IL-7 agent efineptakin alfa was tolerable and led to responses in patients with Kaposi sarcoma, including in HIV-associated disease.

Mevrometostat Plus Enzalutamide Improves rPFS vs Enzalutamide in Metastatic CRPC

February 21st 2025

Pivotal phase 3 trials are ongoing following data from a phase 1 study showing that adding mevrometostat to enzalutamide was safe and efficacious.

Pan-Tumor Approvals Stress the Need for Harmonized Testing and Reporting Strategies

February 21st 2025

Funda Meric-Bernstam, MD, highlights considerations with pan-tumor approvals and where testing and reporting should be improved for clarity/ease.

Critical Next Step in Thymoma/Thymic Carcinoma Field Involves Examining Immunotherapies

February 20th 2025

Rohan Maniar, MD, details considerations when treating patients with rare thymic epithelial tumors as well as notable ongoing research in the field.

Nadofaragene Firadenovec Trial Looks to Prove Efficacy in Intermediate-Risk NMIBC

February 19th 2025

Following its approval in high-risk BCG-unresponsive NMIBC with CIS, nadofaragene firadenovec is being assessed in intermediate-risk disease in ABLE-32.

The Heart of the Matter: Unraveling the Link Between CVD and Breast Cancer for American Heart Month

February 18th 2025

Amy M. Ahnert, MD, highlights newer shared risk factors for CVD and breast cancer and questions regarding personalized screening for the diseases.

A Cardiologist Highlights the Interwoven Elements of CVD and Breast Cancer

February 17th 2025

Amy M. Ahnert, MD, details the significance of findings on the link between CVD and breast cancer as well as next steps to further define the connection.

OPTYX Study Offers Preliminary Glance Into Real-World Use of Relugolix in Advanced Prostate Cancer

February 17th 2025

Patients with advanced prostate cancer who initiated treatment with relugolix indicated various treatment preferences and reasons for therapy initiation.

Real-World Relugolix Adherence Rates Are High in Patients on Medicare With Prostate Cancer

February 17th 2025

Adherence rates improved the longer patients with metastatic and nonmetastatic prostate cancer received relugolix for a high overall adherence rate.

Avutometinib/Defactinib Combo Could Fill Sizeable Unmet Need in LGSOC

February 17th 2025

Ritu Salani, MD, MBA, details the significance of trials examining avutometinib plus defactinib and enthusiasm for ADCs in ovarian cancer.

1.34-mg Dose of Tivozanib Is More Efficacious Than Reduced 0.89-mg Dose in RCC

February 15th 2025

An ER model analysis showed that 1.34 mg of tivozanib provided a greater decrease in tumor size and may be more tolerable than an 0.89-mg dose in RCC.

Orca-Q Shows Promise in High-Risk Hematologic Cancers and BFT Conditioning May Synergize With the Agent

February 14th 2025

One-year follow-up data from an ongoing phase 1 study showed that Orca-Q offered similar benefits as T-cell depletion, without the typical compromises seen.

Orca-T With RIC Is Safe in Advanced Hematologic Malignancies

February 14th 2025

Orca-T with reduced-intensity conditioning displayed robust and early donor myeloid and T-cell engraftment in advanced hematologic malignancies.

Withdrawn Agents, Label Updates, and New Drug Formulations Shaped the Oncology Field in 2024

February 14th 2025

See this full list of regulatory decisions from 2024 regarding withdrawn agents, label updates, and new drug formulations.

Darolutamide Plus ADT Is Efficacious in mHSPC Regardless of Disease Volume

February 13th 2025

The addition of darolutamide to ADT improved rPFS and other efficacy end points vs placebo plus ADT in mHSPC.

2024 FDA Approvals in Breast, Gynecologic, and Other Solid Tumors Represent Key Steps Forward

February 13th 2025

Experts provide insights on the 2024 FDA approvals in several different fields including solid tumors and more in this list featuring the regulatory decisions.

Obe-Cel Represents a Unique CAR T-Cell Therapy for Patients with Relapsed/Refractory ALL

February 12th 2025

Daniel J. DeAngelo, MD, PhD, details how the split dosing of obe-cel yields reduced toxicities and makes it a unique CAR T-cell therapy for relapsed/refractory ALL.

Open Surgery Approaches and Sequencing Considerations Represent Core Parts of the Shifting Cervical Cancer Field

February 12th 2025

Ritu Salani, MD, MBA, details considerations for cervical cancer treatment as new approvals, research, and modalities affect several settings.

Over a Dozen FDA Approvals in 2024 Changed the Lung Cancer Field

February 12th 2025

This full list of 2024 FDA approvals in lung cancer features insights from experts who sat down with us throughout the year to discuss their significance.